Sandoz created a dedicated global biosimilar development, manufacturing, and supply unit to capitalize on the 'golden decade' for biosimilars, with over $650 billion in medicines losing exclusivity from 2026-2030.178
Armin Metzger appointed as President of the new biosimilars unit, starting April 1, 2026.1368
Acquired Just-Evotec Biologics for $650M to secure biomanufacturing capacity in Toulouse, France, and technology licensing for scalable production.1
Reorganization separates biosimilars from generics businesses to accelerate growth and strengthen generics amid price erosion pressures.357
Key 2026 catalysts include Just-Evotec deal closure, first biosimilar launches, and net sales growth acceleration.14
No recent news found in search results on Sanofi shedding its Latin America generics business.
Sources:
1. https://www.ainvest.com/news/sandoz-biosimilars-bet-hinges-2026-catalysts-unit-fire-patent-cliff-2603/
3. https://insights.citeline.com/generics-bulletin/business/strategy/sandoz-splits-out-biosimilars-and-generics-with-new-business-structure-RDAYKCZ3CFBXFN5H2SPL4R6WIQ/
4. https://www.sandoz.com/sandoz-delivers-strong-full-year-results-guidance-2026-reflects-expected-acceleration-growth/
5. https://www.fiercepharma.com/pharma/sandoz-set-standalone-biosimilars-unit-it-eyes-upcoming-golden-decade-patent-losses
6. https://www.tipranks.com/news/company-announcements/sandoz-reshapes-biosimilar-and-generics-leadership-to-seize-upcoming-patent-cliff
7. https://firstwordpharma.com/story/7131922
8. https://www.sandoz.com/sandoz-creates-new-global-biosimilar-development-manufacturing-and-supply-unit-appoints-industry/